|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Bausch_+_Lomb
|
|
gptkbp:activities
|
prostaglandin analog
|
|
gptkbp:administrative_division
|
administer in the evening
|
|
gptkbp:approves
|
gptkb:1996
gptkb:FDA
|
|
gptkbp:average_temperature
|
room temperature
|
|
gptkbp:brand
|
gptkb:Xalatan
|
|
gptkbp:clinical_trial
|
Phase III
long-term treatment
|
|
gptkbp:color
|
clear
|
|
gptkbp:contraindication
|
hypersensitivity to latanoprost
|
|
gptkbp:dosage_form
|
gptkb:sneaker
0.005% solution
|
|
gptkbp:education
|
importance of adherence
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
gptkb:software_framework
|
|
gptkbp:frequency
|
once daily
|
|
gptkbp:has_expansion
|
approximately 300 m Osm/kg
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Xalatan eye drops
|
|
gptkbp:indication
|
intraocular pressure reduction
|
|
gptkbp:ingredients
|
gptkb:latanoprost
|
|
gptkbp:interacts_with
|
other eye medications
|
|
gptkbp:is_available_in
|
multiple countries
|
|
gptkbp:is_monitored_by
|
regular eye exams recommended
|
|
gptkbp:is_used_for
|
gptkb:sneaker
|
|
gptkbp:level
|
6.0 to 7.0
|
|
gptkbp:lifespan
|
17 minutes
|
|
gptkbp:manager
|
ocular
|
|
gptkbp:manufacturer
|
gptkb:Pfizer
|
|
gptkbp:marketed_as
|
gptkb:Xalatan
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:packaging
|
gptkb:beer
|
|
gptkbp:pharmacokinetics
|
rapidly absorbed
|
|
gptkbp:population
|
read before use
|
|
gptkbp:previous_name
|
gptkb:battle
|
|
gptkbp:provides_information_on
|
follow local protocols
|
|
gptkbp:regulatory_body
|
minimal
|
|
gptkbp:requires
|
gptkb:theorem
consult healthcare provider
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:shelf_life
|
2 years
|
|
gptkbp:side_effect
|
dizziness
fatigue
headache
nausea
dry eyes
rash
blurred vision
eye irritation
increased pigmentation of the iris
|
|
gptkbp:suitable_for
|
gptkb:Person
pregnant women
nursing mothers
|
|
gptkbp:traded_on
|
gptkb:Xalatan
|
|
gptkbp:visual_effects
|
may darken eyelashes
|